AI Article Synopsis
- This study evaluates the costs and resource use of different Gonadotropin-Releasing Hormone Agonist (GnRHa) formulations for treating Prostate Cancer in China, focusing on cost minimization strategies.
- It compares "Current practice" of monthly and quarterly GnRHa treatments with a proposed switch to a 6-monthly triptorelin formulation, calculating potential savings and time efficiencies.
- Findings suggest that switching to the 6-monthly treatment could save society over ¥13 million annually and reduce patient treatment time significantly, highlighting its cost-effectiveness compared to more frequent dosing options.
Article Abstract
Objective: Prostate Cancer can be treated with various formulations of Gonadotropin-Releasing Hormone Agonists (GnRHa), but cost analyses of these treatments in China are lacking. This study aims to evaluate the differences in cost and resource utilization between various formulations of GnRHa for Prostate Cancer by conducting a resource utilization assessment and cost minimization analysis.
Methods: From the perspective of society and medical healthcare, this study used the cost minimization model to generate cost and resource estimates for GnRHa drug acquisition and administration for "Current practice" and for a "Base case" scenario. In the "Base case" scenario, all of the patients who were receiving 1-monthly or 3-monthly GnRHa therapy in "Current practice" switched to a 6-monthly formulation triptorelin. Cost/Resource estimates were calculated per patient per administration and scaled to annualized population levels. Deterministic sensitivity analysis was conducted to explore the uncertainty of the model variables and applied assumptions.
Results: From a societal perspective, if all 1-monthly and 3-monthly formulations of GnRHa were switched to a 6-monthly formulation triptorelin, it is conservatively estimated that the annual societal cost could be reduced by ¥13,382,951.13, with an average annual cost savings of ¥46.53 per patient. Additionally, the 6-monthly formulation could save 3,608,973.91 hours annually, translating to an average time savings of 12.55 hours per patient, reducing treatment time by 78%. From a healthcare system perspective, if the introduction of the 6-monthly formulation of GnRHa is delayed, it would lead to an annual increase of ¥94 million in medical costs, and require an additional 64,445.96 working days for doctors and nurses. Deterministic sensitivity analysis demonstrated the model's robustness, showing the 6-monthly GnRHa remains cost-effective across various parameter changes, with drug price being the most influential factor.
Conclusion: Compared to current 1-monthly and 3-monthly formulations, the 6-monthly GnRHa can reduce the total burden associated with prostate cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651073 | PMC |
| http://dx.doi.org/10.2147/CEOR.S485856 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Resources Utilization Assessment and Cost-Minimization Analysis of the 6-Monthly Formulation of Triptorelin in the Treatment of Prostate Cancer in China.
Clinicoecon Outcomes Res
December 2024
Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200000, People's Republic of China.
Article Synopsis
- This study evaluates the costs and resource use of different Gonadotropin-Releasing Hormone Agonist (GnRHa) formulations for treating Prostate Cancer in China, focusing on cost minimization strategies.
- It compares "Current practice" of monthly and quarterly GnRHa treatments with a proposed switch to a 6-monthly triptorelin formulation, calculating potential savings and time efficiencies.
- Findings suggest that switching to the 6-monthly treatment could save society over ¥13 million annually and reduce patient treatment time significantly, highlighting its cost-effectiveness compared to more frequent dosing options.
A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.
Adv Ther
December 2024
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei,, China.
Article Synopsis
- - This phase 3 study evaluated a 6-month prolonged release formulation of triptorelin for treating central precocious puberty (CPP) in Chinese children, focusing on its efficacy, safety, and pharmacokinetics.
- - In an open-label trial involving 66 children (93.9% girls), the treatment successfully suppressed luteinizing hormone (LH) levels in all participants by month 6, with 98.5% maintaining this suppression at month 12, alongside other positive hormone and development outcomes.
- - The study found that triptorelin had a safety profile similar to previous studies in non-Chinese children, with limited adverse events reported, reinforcing its effectiveness and safety in managing CPP.
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
PLoS Med
June 2024
Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Background: In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.
Methods And Findings: In 2 sequential parallel, open-label, randomised controlled trials (the PREVIX trials), eligible infants were first allocated 1:1:1 at age 28 to 38 days to standard or mixed PCV schedules, then at age 12 months to PCV13 (13-valent pneumococcal conjugate vaccine, +P) or PHiD-CV10 (10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine, +S) (1:1).
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
Eur J Drug Metab Pharmacokinet
July 2024
Janssen Research & Development, LLC, Turnhoutseweg 30, 2340, Beerse, Belgium.
Background And Objective: Paliperidone palmitate 6-month (PP6M) intramuscular (IM) injection is the longest-acting treatment available for patients with schizophrenia. A population pharmacokinetic (popPK) modeling and simulation approach was deployed to inform dosing strategies for PP6M.
Methods: The extensive analysis database included 15,932 paliperidone samples from 700 patients receiving gluteal paliperidone palmitate 3-month (PP3M) or PP6M injections in the double-blind phase of a phase-3 noninferiority study (NCT03345342).
HIV epidemiology, prevention, treatment, and implementation strategies for public health.
Lancet
February 2024
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.
The global HIV response has made tremendous progress but is entering a new phase with additional challenges. Scientific innovations have led to multiple safe, effective, and durable options for treatment and prevention, and long-acting formulations for 2-monthly and 6-monthly dosing are becoming available with even longer dosing intervals possible on the horizon. The scientific agenda for HIV cure and remission strategies is moving forward but faces uncertain thresholds for success and acceptability.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!